Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 56,137	$ 20,733
Prepaid expenses and other current assets	348	411
Total current assets	56,485	21,144
Long-term assets
Property and equipment, net	20	22
Operating lease right-of-use assets	195	398
Finance lease right-of-use assets	17	24
Intangible assets, net	15,067	16,525
Other long-term assets		59
Total assets	71,784	38,172
Current liabilities
Accounts payable	3,213	1,995
Accrued compensation	756	283
Accrued clinical trial site costs	3,399	1,999
Operating lease liabilities	220	305
Other current liabilities	408	382
Total current liabilities	7,996	4,964
Long-term liabilities
Contingent liability for Essentialis purchase price	10,138	5,938
Other long-term liabilities		147
Total liabilities	23,778	23,225
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 shares authorized, 79,593,621 and 44,658,054 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.	80	45
Additional paid-in-capital	227,519	172,708
Accumulated deficit	(179,593)	(157,806)
Total stockholders’ equity	48,006	14,947
Total liabilities and stockholders’ equity	71,784	38,172
2017 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	4,777	10,822
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 867	$ 1,354